Th17 Cells and Activated Dendritic Cells Are Increased in Vitiligo Lesions

Background Vitiligo is a common skin disorder, characterized by progressive skin de-pigmentation due to the loss of cutaneous melanocytes. The exact cause of melanocyte loss remains unclear, but a large number of observations have pointed to the important role of cellular immunity in vitiligo pathogenesis. Methodology/Principal Findings In this study, we characterized T cell and inflammation-related dermal dendritic cell (DC) subsets in pigmented non-lesional, leading edge and depigmented lesional vitiligo skin. By immunohistochemistry staining, we observed enhanced populations of CD11c+ myeloid dermal DCs and CD207+ Langerhans cells in leading edge vitiligo biopsies. DC-LAMP+ and CD1c+ sub-populations of dermal DCs expanded significantly in leading edge and lesional vitiligo skin. We also detected elevated tissue mRNA levels of IL-17A in leading edge skin biopsies of vitiligo patients, as well as IL-17A positive T cells by immunohistochemistry and immunofluorescence. Langerhans cells with activated inflammasomes were also noted in lesional vitiligo skin, along with increased IL-1ß mRNA, which suggest the potential of Langerhans cells to drive Th17 activation in vitiligo. Conclusions/Significance These studies provided direct tissue evidence that implicates active Th17 cells in vitiligo skin lesions. We characterized new cellular immune elements, in the active margins of vitiligo lesions (e.g. populations of epidermal and dermal dendritic cells subsets), which could potentially drive the inflammatory responses.

[1]  Sheri L. Riccardi,et al.  Fine-mapping of vitiligo susceptibility loci on chromosomes 7 and 9 and interactions with NLRP1 (NALP1). , 2010, The Journal of investigative dermatology.

[2]  J. Carucci,et al.  Human Langerhans cells induce distinct IL-22-producing CD4+ T cells lacking IL-17 production , 2009, Proceedings of the National Academy of Sciences.

[3]  V. Kuchroo,et al.  Interleukin-17 and type 17 helper T cells. , 2009, The New England journal of medicine.

[4]  J. Carucci,et al.  Myeloid dendritic cells from human cutaneous squamous cell carcinoma are poor stimulators of T-cell proliferation. , 2009, The Journal of investigative dermatology.

[5]  C. Melief,et al.  Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. , 2009, The Journal of investigative dermatology.

[6]  A. Peck,et al.  Breaking old paradigms: Th17 cells in autoimmune arthritis. , 2009, Clinical immunology.

[7]  Lisa C. Zaba,et al.  IL-22-producing "T22" T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. , 2009, The Journal of allergy and clinical immunology.

[8]  Xin Yu,et al.  Targeted depletion of lymphotoxin-alpha-expressing Th1 and Th17 cells inhibits autoimmune disease (48.22) , 2009, The Journal of Immunology.

[9]  Lisa C. Zaba,et al.  Resident and "inflammatory" dendritic cells in human skin. , 2009, The Journal of investigative dermatology.

[10]  T. Taş,et al.  The role of helper and regulatory T cells in the pathogenesis of vitiligo. , 2009, Journal of the American Academy of Dermatology.

[11]  M. Picardo,et al.  Clinical practice. Vitiligo. , 2009, The New England journal of medicine.

[12]  Lisa C. Zaba,et al.  Th17 cytokines interleukin (IL)‐17 and IL‐22 modulate distinct inflammatory and keratinocyte‐response pathways , 2008, The British journal of dermatology.

[13]  James T. Elder,et al.  Induction of IL-17+ T Cell Trafficking and Development by IFN-γ: Mechanism and Pathological Relevance in Psoriasis1 , 2008, The Journal of Immunology.

[14]  J. Ward,et al.  Th1, Th2, and Th17 Effector T Cell-Induced Autoimmune Gastritis Differs in Pathological Pattern and in Susceptibility to Suppression by Regulatory T Cells1 , 2008, The Journal of Immunology.

[15]  P. Muranski,et al.  Tumor-specific Th17-polarized cells eradicate large established melanoma. , 2008, Blood.

[16]  Lisa C. Zaba,et al.  Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. , 2008, The Journal of investigative dermatology.

[17]  K. Wittkowski,et al.  Identification of Cellular Pathways of “Type 1,” Th17 T Cells, and TNF- and Inducible Nitric Oxide Synthase-Producing Dendritic Cells in Autoimmune Inflammation through Pharmacogenomic Study of Cyclosporine A in Psoriasis1 , 2008, The Journal of Immunology.

[18]  Lisa C. Zaba,et al.  Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses , 2007, The Journal of experimental medicine.

[19]  J. Tschopp,et al.  The inflammasome: a danger sensing complex triggering innate immunity. , 2007, Current opinion in immunology.

[20]  M. Röcken,et al.  Immunopathogenesis and role of T cells in psoriasis. , 2007, Clinics in dermatology.

[21]  R. Steinman,et al.  Normal human dermis contains distinct populations of CD11c+BDCA-1+ dendritic cells and CD163+FXIIIA+ macrophages. , 2007, The Journal of clinical investigation.

[22]  Kathleen M. Smith,et al.  Development, cytokine profile and function of human interleukin 17–producing helper T cells , 2007, Nature Immunology.

[23]  Sunit P. Jariwala,et al.  The role of dendritic cells in the immunopathogenesis of psoriasis , 2007, Archives of Dermatological Research.

[24]  F. Sallusto,et al.  Interleukins 1β and 6 but not transforming growth factor-β are essential for the differentiation of interleukin 17–producing human T helper cells , 2007, Nature Immunology.

[25]  T. Kopp,et al.  Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells , 2007, The Journal of experimental medicine.

[26]  K. Wittkowski,et al.  Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis , 2007, Journal of Translational Medicine.

[27]  J. Carucci,et al.  Major differences in inflammatory dendritic cells and their products distinguish atopic dermatitis from psoriasis. , 2007, The Journal of allergy and clinical immunology.

[28]  V. Kuchroo,et al.  TH-17 cells in the circle of immunity and autoimmunity , 2007, Nature Immunology.

[29]  Sheri L. Riccardi,et al.  NALP1 in vitiligo-associated multiple autoimmune disease. , 2007, The New England journal of medicine.

[30]  M. Lebwohl,et al.  A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. , 2007, The New England journal of medicine.

[31]  Judy H. Cho,et al.  A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease Gene , 2006, Science.

[32]  M. Nishimura,et al.  Therapeutic implications of autoimmune vitiligo T cells. , 2006, Autoimmunity reviews.

[33]  H. Weiner,et al.  Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells , 2006, Nature.

[34]  J. Edmonds,et al.  Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort). , 2006, Arthritis and rheumatism.

[35]  R. J. Hocking,et al.  TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. , 2006, Immunity.

[36]  Y. Tokura,et al.  Vitiligo with inflammatory raised borders, associated with atopic dermatitis , 2006, Clinical and experimental dermatology.

[37]  R. Steinman,et al.  Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[38]  R. D. Hatton,et al.  Interleukin 17–producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages , 2005, Nature Immunology.

[39]  F. Martinon,et al.  NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. , 2004, Immunity.

[40]  F. Benvenuto,et al.  Molecular and functional bases of self-antigen recognition in long-term persistent melanocyte-specific CD8+ T cells in one vitiligo patient. , 2003, The Journal of investigative dermatology.

[41]  G. Ogg,et al.  Immunopolarization of CD4+ and CD8+ T Cells to Type-1–Like is Associated with Melanocyte Loss in Human Vitiligo , 2003, Laboratory Investigation.

[42]  J. Naeyaert,et al.  Evidence for an autoimmune pathogenesis of vitiligo. , 2003, Pigment cell research.

[43]  J. Becker,et al.  Accumulation of identical T cells in melanoma and vitiligo-like leukoderma. , 1999, The Journal of investigative dermatology.

[44]  Mackie,et al.  Immunohistochemistry and sentinel node biopsy in melanoma: the use of tyrosinase and Melan‐A , 1999, The British journal of dermatology.

[45]  Z. Orosz.  Melan‐A/Mart‐1 expression in various melanocytic lesions and in non‐melanocytic soft tissue tumours , 1999, Histopathology.

[46]  P. Kivisäkk,et al.  Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis , 1999, Multiple sclerosis.

[47]  Yao-Tseng Chen,et al.  Serological analysis of Melan-A(MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[48]  W. Westerhof,et al.  Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance. , 1996, The American journal of pathology.

[49]  E. Latz,et al.  The Inflammasome , 2013, Methods in Molecular Biology.

[50]  D. Gawkrodger,et al.  Autoantigens in vitiligo identified by the serological selection of a phage-displayed melanocyte cDNA expression library. , 2010, The Journal of investigative dermatology.

[51]  N. J. Eungdamrong,et al.  Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. , 2009, The Journal of investigative dermatology.

[52]  Carl G. Figdor,et al.  Vaccine-specific local T cell reactivity in immunotherapy-associated vitiligo in melanoma patients , 2008, Cancer Immunology, Immunotherapy.

[53]  S. Skurkovich,et al.  Inhibition of IFN-gamma as a method of treatment of various autoimmune diseases, including skin diseases. , 2006, Ernst Schering Research Foundation workshop.

[54]  T. Tüting,et al.  Peripheral CD8+ T cell tolerance against melanocytic self-antigens in the skin is regulated in two steps by CD4+ T cells and local inflammation: implications for the pathophysiology of vitiligo. , 2005, The Journal of investigative dermatology.

[55]  T. Tüting,et al.  Initiation and regulation of CD8+T cells recognizing melanocytic antigens in the epidermis: implications for the pathophysiology of vitiligo. , 2004, European journal of cell biology.

[56]  P. Das,et al.  Autoimmune aspects of depigmentation in vitiligo. , 2004, The journal of investigative dermatology. Symposium proceedings.

[57]  K. Thomsen,et al.  Prevalence of vitiligo. Epidemiological survey on the Isle of Bornholm, Denmark. , 1977, Archives of dermatology.